How can we achieve universal access to low-cost treatment for HIV?

Mass production of low-cost antiretrovirals (ARVs) has already allowed over 17 million individuals to access treatment for HIV infection, mainly in low-income countries. It is possible to manufacture combination ARVs for $110 per person-year, using tenofovir (TDF), lamivudine (3TC) and efavirenz (EF...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Andrew M, Pozniak, Anton L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075345/
https://www.ncbi.nlm.nih.gov/pubmed/27781100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075345/
https://www.ncbi.nlm.nih.gov/pubmed/27781100

Ejemplares similares